Patients receiving BCMA-CAR-T cells had seroprotection to fewer pathogens than those receiving CD19-CAR-T cells ( Fig 2B ), but the difference did not reach statistical significance ( Fig 3 ).
← all excerpts
196. Antibodies to Vaccine-preventable Infections After CAR-T Cell Immunotherapy for B Cell Malignancies
1
—
—